A trial using markers to help work out how well new treatments work for triple negative breast cancer (PHOENIX)

This trial is using biomarkers to assess how well a new treatment is working. Researchers do this by collecting tumour biopsies and blood samples before and after treatment. This is in the short 2 week period between completing chemotherapy and having surgery.

The trial is looking at different treatments. It is for people who have chemotherapy before surgery but the cancer doesn’t go away completely.

Triple negative breast cancer is cancer without receptors for:

• oestrogen

• progesterone

• HER2

Cancer Research UK supports this trial.